Study of Blood Protein O-GlcNAcylation Levels in Children Up to 17 Years Comparing Healthy Children and Those with Septic Shock

What this Trial Is About

Sepsis is a leading cause of death and disability in children worldwide, with a particularly high mortality rate in young children. This research aims to evaluate blood protein O-GlcNAcylation levels in children, a process shown in animal studies to improve cardiac function and survival during septic shock and other acute conditions. Understanding this process in children could lead to better management of septic shock and other systemic inflammatory responses in pediatric patients. The study observes two groups of children healthy children undergoing routine blood tests for various medical reasons and children experiencing septic shock requiring intensive care and vascular filling. Blood samples will be collected at inclusion and multiple time points over 48 hours to measure O-GlcNAcylation levels and assess their relationship with septic shock severity. The study is observational and does not involve any investigational drug or treatment but collects clinical data from medical records. Participants will provide blood samples during their hospital visits or stays, with clinical data recorded in their medical files. Blood samples will be taken once or multiple times depending on the group and clinical need. Researchers will analyze O-GlcNAcylation levels at inclusion and compare them between healthy children and those in septic shock. Long-term follow-up of up to 5 years will assess links between these levels and patient prognosis. The study spans from 2025 to 2036, focusing on children from birth to 17 years old.

Evaluation of Blood Protein O-GlcNAcylation Levels in Children